Consistent with previous studies of ADPKD models, we find that treatment with the AURKA kinase inhibitor Alisertib increases cyst number in JS mice and that this is linked to an unexpected accumulation of AURKA following drug treatment and AKT activation. This evidence concerns the gene AKT1 and autosomal dominant polycystic kidney disease.